Role of IL-9 and STATs in hematological malignancies (Review)

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 602-610

  Chen, Na ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hematological malignancies; IL 9; STAT3; STAT6

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; GLYCOPROTEIN GP 130; GROWTH HORMONE; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 9; JANUS KINASE 1; MONOCLONAL ANTIBODY; NUCLEOPHOSMIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STAT PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TAX PROTEIN; TRANSCRIPTION FACTOR;

CD4+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE REPRESSION; HEMATOLOGIC MALIGNANCY; HISTOCOMPATIBILITY GENE; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; RNA INTERFERENCE; T CELL LEUKEMIA; TH17 CELL; TH2 CELL; TREATMENT PLANNING;

EID: 84892966814     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1761     Document Type: Review

References (91)

1. Namkung JH, Lee JE, Kim E, et al: An association between IL-9 and IL-9 receptor gene polymorphisms and atopic dermatitis in a Korean population. J Dermatol Sci 62: 16-21, 2011.
2. Knoops L and Renauld JC: IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 22: 207-215, 2004.
3. Putheti P, Awasthi A, Popoola J, Gao W and Strom TB: Human CD4 memory T cells can become CD4+IL-9+ T cells. PLoS One5: e8706, 2010.
4. van den Ham HJ, de Waal L, Andeweg AC and de Boer RJ: Identification of helper T cell master regulator candidates using the polar score method. J Immunol Methods 361: 98-109, 2010.
5. Chang HC, Han L, Jabeen R, Carotta S, Nutt SL and Kaplan MH: PU.1 regulates TCR expression by modulating GATA-3 activity. J Immunol 183: 4887-4894, 2009.
6. Chang HC, Zhang S, Thieu VT, Slee RB, Bruns HA, LaribeeRN, Klemsz MJ and Kaplan MH: PU.1 expression delineates heterogeneity in primary Th2 cells. Immunity 22: 693-703, 2005.
7. Chang HC, Sehra S, Goswami R, Yao W, Yu Q, StriteskyGL, Jabeen R, McKinley C, Ahyi AN, Han L, etal: The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol11: 527-534, 2010.
8. Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, Grebe N, Gerlitzki B, Hoffmann M, Ulges A, Taube C, etal: Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity33: 192-202, 2010.
9. Ahyi AN, Chang HC, Dent AL, Nutt SL and Kaplan MH: IFN regulatory factor 4 regulates the expression of a subset of Th2 cytokines. J Immunol 183: 1598-1606, 2009.
10. Brustle A, Heink S, Huber M, Rosenplanter C, StadelmannC, YuP, Arpaia E, Mak TW, Kamradt T and Lohoff M: The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol8: 958-966, 2007.
11. Lohoff M, Mittrucker HW, Prechtl S, Bischof S, Sommer F, Kock S, Ferrick DA, Duncan GS, Gessner A and Mak TW: Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4. Proc Natl Acad Sci USA99: 11808-11812, 2002.
12. Hültner L, Kölsch S, Stassen M, Kaspers U, Kremer JP, Mailhammer R, Moeller J, Broszeit H and Schmitt E: In activated mast cells, IL-1 up-regulates the production of several Th2-related cytokines including IL-9. J Immunol 164: 5556-5563, 2000.
13. Stassen M, Arnold M, Hültner L, Müller C, Neudörfl C, Reineke T and Schmitt E: Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1. J Immunol 164: 5549-5555, 2000.
14. Stassen M, Müller C, Arnold M, Hültner L, Klein-HesslingS, Neudörfl C, Reineke T, Serfling E and Schmitt E: IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol 166: 4391-4398, 2001.
15. Stassen M, Klein M, Becker M, Bopp T, Neudörfl C, RichterC, Heib V, Klein-Hessling S, Serfling E, Schild H and SchmittE: p38 MAP kinase drives the expression of mast cell-derived IL-9 via activation of the transcription factor GATA-1. Mol Immunol44: 926-933, 2007.
16. Osterfeld H, Ahrens R, Strait R, Finkelman FD, Renauld JC and Hogan SP: Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis. J Allergy Clin Immunol 125: 469-476, 2010.
17. Demoulin JB, Louahed J, Dumoutier L, Stevens M and RenauldJC: MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene 22: 1763-1770, 2003.
18. Cosmi L, Liotta F, Angeli R, Mazzinghi B, Santarlasci V, ManettiR, Lasagni L, Vanini V, Romagnani P, Maggi E, etal: Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 103: 3117-3121, 2004.
19. Druez C, Coulie P, Uyttenhove C and Van Snick J: Functional and biochemical characterization of mouse P40/IL-9 receptors. J Immunol 145: 2494-2499, 1990.
20. Abdelilah S, Latifa K, Esra N, Cameron L, Bouchaib L, Nicolaides N, Levitt R and Hamid Q: Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release. J Immunol 166: 2768-2774, 2001.
21. Kearley J, Erjefalt JS, Andersson C, Benjamin E, Jones CP, Robichaud A, Pegorier S, Brewah Y, Burwell TJ, Bjermer L, etal: IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med183: 865-875, 2011.
22. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, Coyle AJ, Kasper LH and Noelle RJ: IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 206: 1653-1660, 2009.
23. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, etal: Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997-1002, 2006.
24. Knoops L, Louahed J and Renauld JC: IL-9-induced expansion of B-1b cells restores numbers but not function of B-1 lymphocytes in xid mice. J Immunol 172: 6101-6106, 2004.
25. Vink A, Warnier G, Brombacher F and Renauld JC: Interleukin9-induced in vivo expansion of the B-1 lymphocyte population. J Exp Med 189: 1413-1423, 1999.
26. Dugas B, Renauld JC, Pene J, Bonnefoy JY, Peti-Frère C, BraquetP, Bousquet J, Van Snick J and Mencia-Huerta JM: Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol 23: 1687-1692, 1993.
27. Petit-Frere C, Dugas B, Braquet P and Mencia-Huerta JM: Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology 79: 146-151, 1993.
28. Fawaz LM, Sharif-Askari E, Hajoui O, Soussi-Gounni A, HamidQ and Mazer BD: Expression of IL-9 receptor alpha chain on human germinal center B cells modulates IgE secretion. J Allergy Clin Immunol 120: 1208-1215, 2007.
29. Renauld JC, Druez C, Kermouni A, Houssiau F, Uyttenhove C, Van Roost E and Van Snick J: Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci USA 89: 5690-5694, 1992.
30. Chen J, Petrus M, Bryant BR, Phuc Nguyen V, Stamer M, GoldmanCK, Bamford R, Morris JC, Janik JE and WaldmannTA: Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 111: 5163-5172, 2008.
31. Umezu-Goto M, Kajiyama Y, Kobayashi N, Kaminuma O, SukoM and Mori A: IL-9 production by peripheral blood mononuclear cells of atopic asthmatics. Int Arch Allergy Immunol143 (Suppl 1): 76-79, 2007.
32. Chen J, Petrus M, Bryant BR, Nguyen VP, Goldman CK, BamfordR, Morris JC, Janik JE and Waldmann TA: Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood116: 5948-5956, 2010.
33. Merz H, Kaehler C, Hoefig KP, et al: Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice. Oncotarget 1: 104-119, 2010.
34. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, GrammatikakisI, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, etal: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167: 969-980, 2005.
35. Dahéron L, Opitz SL, Zaehres H, Lensch MW, Andrews PW, Itskovitz-Eldor J and Daley GQ: LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells 22: 770-778, 2004.
36. Raptis L, Arulanandam R, Geletu M and Turkson J: The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. Exp Cell Res317: 1787-1795, 2011.
37. Kidder BL, Yang J and Palmer S: STAT3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS One 3: e3932, 2008.
38. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, OrlovYL, Zhang W, Jiang J, etal: Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133: 1106-1117, 2008.
39. Kuznetsov VA, Singh O and Jenjaroenpun P: Statistics of protein-DNA binding and the total number of binding sites for a transcription factor in the mammalian genome. BMC Genomics 11 (Suppl 1): S12, 2010.
40. Ying QL, Nichols J, Chambers I and Smith A: BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115: 281-292, 2003.
41. Ramana CV, Chatterjee-Kishore M, Nguyen H and StarkGR: Complex roles of STAT1 in regulating gene expression. Oncogene19: 2619-2627, 2000.
42. Bourillot PY, Aksoy I, Schreiber V, Wianny F, Schulz H, HummelO, Hubner N and Savatier P: Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells27: 1760-1771, 2009.
43. Yu Z, Zhang W and Kone BC: Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor κB. Biochem J 367: 97-105, 2002.
44. Zhang X, Wrzeszczynska MH, Horvath CM and Darnell JE Jr: Interacting regions in STAT3 and c-Jun that participate in cooperative transcriptional activation. Mol Cell Biol 19: 7138-7146, 1999.
45. Giraud S, Bienvenu F, Avril S, Gascan H, Heery DM and CoqueretO: Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem 277: 8004-8011, 2002.
46. Youn MY, Yoo HS, Kim MJ, Hwang SY, Choi Y, Desiderio SV and Yoo JY: hCTR9, a component of Paf1 complex, participates in the transcription of interleukin 6-responsive genes through regulation of STAT3-DNA interactions. J Biol Chem282: 34727-34734, 2007.
47. Ni Z and Bremner R: Brahma-related gene 1-dependent STAT3 recruitment at IL-6-inducible genes. J Immunol 178: 345-351, 2007.
48. Giraud S, Hurlstone A, Avril S and Coqueret O: Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene. Oncogene 23: 7391-7398, 2004.
49. Ho L, Jothi R, Ronan JL, Cui K, Zhao K and Crabtree GR: An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network. Proc Natl Acad Sci USA 106: 5187-5191, 2009.
50. Ho L, Ronan JL, Wu J, Staahl BT, Chen L, Kuo A, Lessard J, Nesvizhskii AI, Ranish J and Crabtree GR: An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proc Natl Acad Sci USA 106: 5181-5186, 2009.
51. Singhal N, Graumann J, Wu G, Araúzo-Bravo MJ, HanDW, GreberB, Gentile L, Mann M and Schöler HR: Chromatin-remodeling components of the BAF complex facilitate reprogramming. Cell141: 943-955, 2010.
52. Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland ML, LeGouvello S, Gaulard P, Leroy K and Castellano F: Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 104: 543-549, 2004.
53. Gerber M and Shilatifard A: Transcriptional elongation by RNA polymerase II and histone methylation. J Biol Chem278: 26303-26306, 2003.
54. Ding L, Paszkowski-Rogacz M, Nitzsche A, Slabicki MM, Heninger AK, de Vries I, Kittler R, Junqueira M, ShevchenkoA, Schulz H, etal: A genome-scale RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic stem cell identity. Cell Stem Cell 4: 403-415, 2009.
55. Ponnusamy MP, Deb S, Dey P, Chakraborty S, Rachagani S, Senapati S and Batra SK: RNA polymerase II associated factor 1/PD2 maintains self-renewal by its interaction with Oct3/4 in mouse embryonic stem cells. Stem Cells 27: 3001-3011, 2009.
56. Lessard JA and Crabtree GR: Chromatin regulatory mechanisms in pluripotency. Annu Rev Cell Dev Biol 6: 503-532, 2010.
57. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, TrumperL, Kapp U and Mak TW: Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99: 618-626, 2002.
58. Wei L, Vahedi G, Sun HW, Watford WT, Takatori H, RamosHL, Takahashi H, Liang J, Gutierrez-Cruz G, Zang C, etal: Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity32: 840-851, 2010.
59. Elo LL, Järvenpää H, Tuomela S, Raghav S, Ahlfors H, LaurilaK, Gupta B, Lund RJ, Tahvanainen J, Hawkins RD, etal: Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity 32: 852-862, 2010.
60. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T and Akira S: Essential role of STAT6 in IL-4 signalling. Nature 380: 627-630, 1996.
61. Ansel KM, Djuretic I, Tanasa B and Rao A: Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol24: 607-656, 2006.
62. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, SobelRA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, Khoury S, OukkaM and Kuchroo VK: IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 9: 1347-1355, 2008.
63. Perumal NB and Kaplan MH: Regulating Il9 transcription in Thelper cells. Trends Immunol 32: 146-150, 2011.
64. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, WestendorfA, Buer J, Martin B, Wilhelm and Stockinger B: Transforming growth factor-beta 'reprograms' the differentiation of T helper2 cells and promotes an interleukin 9-producing subset. Nat Immunol 9: 1341-1346, 2008.
65. Kaplan MH, Daniel C, Schindler U and Grusby MJ: STAT proteins control lymphocyte proliferation by regulating p27Kip1 expression. Mol Cell Biol 18: 1996-2003, 1998.
66. Zhu J, Guo L, Min B, Watson CJ, Hu-Li J, Young HA, TsichlisPN and Paul WE: Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity 16: 733-744, 2002.
67. Kaplan MH, Wurster AL, Smiley ST and Grusby MJ: STAT6-dependent and-independent pathways for IL-4 production. J Immunol 163: 6536-6540, 1999.
68. Bruns HA, Schindler U and Kaplan MH: Expression of a constitutively active STAT6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J Immunol 170: 3478-3487, 2003.
69. Kaplan MH, Whitfield JR, Boros DL and Grusby MJ: Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. J Immunol 160: 1850-1856, 1998.
70. Wurster AL, Rodgers VL, White MF, Rothstein TL and GrusbyMJ: Interleukin-4-mediated protection of primary B cells from apoptosis through STAT6-dependent up-regulation of Bcl-xL. J Biol Chem 277: 27169-27175, 2002.
71. Takeda K, Kamanaka M, Tanaka T, Kishimoto T and AkiraS: Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 157: 3220-3222, 1996.
72. Martinez FO, Helming L and Gordon S: Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27: 451-483, 2009.
73. Huber S, Hoffmann R, Muskens F and Voehringer D: Alternatively activated macrophages inhibit T-cell proliferation by STAT6-dependent expression of PD-L2. Blood 116: 3311-3320, 2010.
74. Szanto A, Balint BL, Nagy ZS, Barta E, Dezso B, Pap A, Szeles L, Poliska S, Oros M, Evans RM, etal: STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity33: 699-712, 2010.
75. Yao Y, Li W, Kaplan MH and Chang CH: Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med 201: 1899-1903, 2005.
76. Furqan M, Mukhi N, Lee B and Liu D: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1: 5, 2013.
77. Bito T, Sumita N, Ashida M, Budiyanto A, Ueda M, Ichihashi M, Tokura Y and Nishigori C: Inhibition of epidermal growth factor receptor and PI3K/Akt signaling suppresses cell proliferation and survival through regulation of Stat3 activation in human cutaneous squamous cell carcinoma. J Skin Cancer2011: 874571, 2011.
78. Jeres A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-SeguiI, etal: STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120: 3048-3057, 2012.
79. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ and Estrov Z: STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115: 2852-2863, 2010.
80. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, ZhangY, Cattoretti G and Ye BH: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111: 1515-1523, 2008.
81. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, Dubois G, Gaulard P, Moller P and Leroy K: Recurrent mutations of theSTAT6DNA binding domain in primary mediastinal B-cell lymphoma. Blood114: 1236-1242, 2009.
82. Kis LL, Gerasimcik N, Salamon D, Persson EK, Nagy N, Klein G, Severinson E and Klein E: STAT6signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood117: 165-174, 2011.
83. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, PestellRG, Albanese C and Darnell JE Jr: STAT3 as an oncogene. Cell98: 295-303, 1999.
84. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
85. Haura EB, Turkson J and Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2: 315-324, 2005.
86. Frank DA, Mahajan S and Ritz J: B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 100: 3140-3148, 1997.
87. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, etal: Constitutive activation of STAT3 in human proSTATe tumors and cell lines: direct inhibition of STAT3 signaling induces apoptosis of proSTATe cancer cells. Cancer Res 62: 6659-6666, 2002.
88. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, EweisI, Wloch M, Livingston S, Seijo E, etal: Activation of STAT3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12: 20-28, 2006.
89. Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, HauffP, Schirner M, Wiedenmann B and Rosewicz S: Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125: 891-905, 2003.
90. Eifan AO, Furukido K, Dumitru A, Jacobson MR, Schmidt-WeberC, Banfield G, Durham SR and Nouri-Aria KT: Reduced T-bet in addition to enhanced STAT6 and GATA3 expressing T cells contribute to human allergen-induced late responses. Clin Exp Allergy 42: 891-900,2012.
91. Hadjur S, Bruno L, Hertweck A, Cobb BS, Taylor B, Fisher AG and Merkenschlager M: IL4 blockade of inducible regulatory T cell differentiation: the role of Th2 cells, Gata3 and PU.1. Immunol Lett 122: 37-43, 2009.